Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Chicago
Amgen
University of Maryland, Baltimore
BioNTech SE
NRG Oncology
Sichuan University
Mayo Clinic
Swiss Cancer Institute
Memorial Sloan Kettering Cancer Center
Ohio State University Comprehensive Cancer Center
Vanderbilt-Ingram Cancer Center
Fox Chase Cancer Center